Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.70 |
| ▸ | MAOB | P27338 | 4/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.70 |
| ▸ | SDHA | P31040 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | CALML3 | P27482 | 1/20 | 0.70 |
| ▸ | F10 | P00742 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1033024 | 1.00 | MAOA (0.70) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL16701350 | 0.90 | MAOA (0.74) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL16701349 | 0.90 | MAOA (0.74) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5917645 | 0.89 | MAOA (0.56) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL12950996 | 0.89 | MAOA (0.72) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6097822 | 0.89 | MAOA (0.72) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3328443 | 0.89 | MAOA (0.76) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3328441 | 0.89 | MAOA (0.76) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL13034192 | 0.89 | MAOA (0.72) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL2088204 | 0.88 | MAOA (0.71) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118164975-B | Quaternary ammonium salt oxazolidinone derivative and pharmaceutically acceptable salt thereof, preparation method and application | 中国医学科学院医药生物技术研究所 | 2024-08-09 | — | — | CN | disclosed |
| CN-118164975-A | Quaternary ammonium salt oxazolidinone derivative and pharmaceutically acceptable salt thereof, preparation method and application | 中国医学科学院医药生物技术研究所 | 2024-06-11 | — | — | CN | disclosed |
| EP-3442526-B1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA SUBSIDIARY CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-108976222-B | Heterocyclic ring-containing biaryl oxazolidinone compound and preparation method thereof | 沈阳药科大学 | 2021-09-03 | — | — | CN | disclosed |
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | MELINTA SUBSIDARY CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3442526-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Melinta Subsidiary Corp. (US) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017200979-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA THERAPEUTICS, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA SUBSIDIARY CORP. | 2017-11-23 | — | — | US | disclosed |
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA SUBSIDIARY CORP. | 2017-11-23 | — | — | US | disclosed |
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA SUBSIDIARY CORP. | 2017-11-23 | — | — | US | disclosed |
| EP-0856002-A1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | PHARMACIA & UPJOHN COMPANY (US) | 1998-08-05 | — | — | EP | disclosed |
| EP-0673370-B1 | TROPONE-SUBSTITUTED PHENYLOXAZOLIDINONE ANTIBACTERIAL AGENTS | UPJOHN CO (US) | 1998-01-07 | — | — | EP | disclosed |
| US-5654428-A | BACTERICIDES | PHARMACIA & UPJOHN COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| WO-1997009328-A1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | PHARMACIA & UPJOHN COMPANY (US) | 1997-03-13 | — | — | WO | disclosed |
| EP-0610265-B1 | SUBSTITUTED ARYL- AND HETEROARYLPHENYLOXAZOLIDINONES USEFUL AS ANTIBACTERIAL AGENTS | UPJOHN CO (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5523403-A | Tropone-substituted phenyloxazolidinone antibacterial agents | THE UPJOHN COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0673370-A1 | TROPONE-SUBSTITUTED PHENYLOXAZOLIDINONE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1995-09-27 | — | — | EP | disclosed |
| EP-0610265-A1 | SUBSTITUTED ARYL- AND HETEROARYLPHENYLOXAZOLIDINONES USEFUL AS ANTIBACTERIAL AGENTS. | UPJOHN CO (US) | 1994-08-17 | — | — | EP | disclosed |
| WO-1994013649-A1 | TROPONE-SUBSTITUTED PHENYLOXAZOLIDINONE ANTIBACTERIAL AGENTS | THE UPJOHN COMPANY (US) | 1994-06-23 | — | — | WO | disclosed |
| WO-1993009103-A1 | SUBSTITUTED ARYL- AND HETEROARYLPHENYLOXAZOLIDINONES USEFUL AS ANTIBACTERIAL AGENTS | THE UPJOHN COMPANY (US) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333400-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CUTA, CYP19A1, KAT2A | MAOA 379/4885MAOB 219/4885PTGS1 2113/4885 |
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | CUTA, CYP17A1, HSD17B11 | MAOA 1569/4885MAOB 1093/4885PTGS1 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.